Skip to Main Content

Advertisement

Skip Nav Destination

A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT

Blood Adv (2023) 7 (3): 285–292.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement